Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs

British Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 496-501

  Downing, Amy ^a,e   Jacobsen, Jacob ^b   Sorensen, Henrik T ^b   McLaughlin, Joseph K ^c,d   Johnsen, Soren P ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

Angio oedema; COX 2 selective inhibitors; Epidemiology; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR; ANTIBIOTIC AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRIDAMOLE; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHENPROCOUMON; ROFECOXIB; WARFARIN;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE REGISTRY; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPOTHESIS; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANGIOEDEMA; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2 INHIBITORS; DENMARK; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33748752301     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02753.x     Document Type: Article

References (32)

1. Rodriguez G, Alberto L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
2. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 2003; 24: 125-35.
3. Joint Task Force on Practice Parameters. Part 1: Acute urticaria/angioedema. Ann Allergy Asthma Immunol 2000; 85: 525-31.
4. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43.
5. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursin B, Mungan D, Misirligil Z. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 2005; 42: 127-31.
6. Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Berges-Gimeno MP, Martin Garcia C. Celecoxib, safe in NSAID intolerance. Allergy 2002; 57: 1085-6.
7. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002; 32: 397-400.
8. Quiralte J, Saenz de San Pedro B, Florido JF. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89: 63-6.
9. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors. J Allergy Clin Immunol 2002; 109: 370.
10. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 2001; 28: 2553-4.
11. Marshall LL. Angioedema associated with aspirin and rofecoxib. Ann Pharamacother 2005; 39: 944-8.
12. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: WHO 1992.
13. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies, I. Principles. Am J Epidemiol 1991; 134: 433-7.
14. Quiralte J, Blanco C, Castillo R, Delgado J, Carillo T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996; 98: 678-85.
15. Greenland S. Modelling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-9.
16. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema. Am J Clin Dermatol 2002; 3: 599-607.
17. Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL. Adverse drug events involving COX-2 inhibitors. Ann Pharamacother 2003; 37: 1203-13.
18. Layton D, Wilton LV, Shakir SAW. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Eur J Clin Pharmacol 2004; 60: 489-501.
19. Layton D, Riley J, Wilton LV, Shakir SAW. Safety profile of rofecoxib as used in general practice in England: results of a prescriptionevent monitoring study. Br J Clin Pharmacol 2003; 55: 166-74.
20. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Ramon Perez C. Tolerability to new COX-2 inhibitors in NSAID sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001; 87: 201-4.
21. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, Romagnani S. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004; 59: 1133-4.
22. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and longterm tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005; 94: 29-33.
23. GISED. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993; 186: 164-9.
24. Figueras A, Capella D, Castel JM, Laorte JR. Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 1994; 47: 297-303.
25. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann All Asthma Immunol 2005; 94: 34-8.
26. Grattan CEH. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28: 123-7.
27. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID hypersensitivity in the COX-2 inhibitor era. Allergy Clin Immunol Int 2001; 13: 211-8.
28. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31: 219-25.
29. La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Safety 2005; 28: 917-24.
30. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of NSAIDs, COX-2 inhibitors and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002; 47: 595-602.
31. Zhao SZ, Burke TA, Whelton A, von Allmen A, Henderson SC. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2 specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am J Manag Care 2002; 8 (Suppl.): S392-400.
32. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary sources for epidemiological research. Int J Epidemiol 1996; 25: 435-42.